ProCE Banner Activity

Tucatinib + Trastuzumab for Previously Treated Advanced HER2+ Biliary Tract Cancer

Conference Coverage
Slideset

Tucatinib + trastuzumab was associated with a clinically meaningful ORR of 46.7% in patients with previously treated advanced HER2+ biliary tract cancer.

Released: June 08, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Merck Sharp & Dohme Corp., Novocure, and Seagen.

Merck Sharp & Dohme Corp.

Novocure

Seagen